ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 509

Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative

Kathy Cui1, Mohammad Movahedi2, Claire Bombardier3 and Bindee Kuriya4,5,6, 1Western University, London Health Sciences Centre, London, ON, Canada, 2JSS Medical Research, St-Laurent, QC, Canada, 3Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 4Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Sinai Health System, University of Toronto, Toronto, ON, Canada, 6Rheumatology, University of Toronto, Toronto, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Disability, Disease Activity, outcomes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis increases the risk of cardiovascular disease (CVD). Less is known about the direct influence of CVD on RA outcomes, but higher comorbidity burden has been suggested to adversely affect RA treatment response. We tested our hypothesis that CVD risk factors (RFs) alone, in the absence of CVD, are associated with higher disease activity and disability in RA.

Methods: The Ontario Best Practices Research Initiative (OBRI) is a clinical registry of RA patients followed in routine care. RA subjects with complete data to calculate disease activity according to the Disease Activity Score-28 (DAS28), Clinical Disease Activity Index (CDAI), 28 swollen joint count (SJC28) and functional status (Health Assessment Questionnaire Disability Index [HAQ-DI]) at cohort entry were selected. Patients were divided into mutually exclusive groups by baseline CVD status as: (1) no CVD/no CVD RFs; (2) CVD; (3) no CVD but CVD RFs including hypertension (HTN), dyslipidemia (DLP), diabetes (DM), or smoking. We performed separate linear regression analyses, adjusted for baseline clinical and demographic variables, to determine the independent effect of CVD status on disease outcomes at baseline.

Results: Of 2033 patients examined, 54% had no CVD, 5% had CVD and 41% had CVD RFs alone. The most common RF was HTN (23%) followed by current smoking (17%), DM (12%) and DLP (5%). The majority had 1 CVD RF (34%) with decreasing frequency of 2 (8%), 3(2%) or all 4 (0.3%) risk factors. Subjects with CVD or CVD RFs were significantly older, had less education, higher ESR, higher joint counts, higher pain scores and greater number of non-CVD comorbidities. In cross-sectional analyses, having a CVD RF was associated with significantly higher composite disease activity scores (DAS28 and CDAI), and HAQ-DI scores (Table). No association between CVD status and swollen joint count was observed.

Conclusion: Even in the absence of CVD, traditional CVD risk factors are associated with greater RA disease severity and disability. Self-perceived impact of comorbidity (patient global assessment of health) may be driving this relationship. Investigation into the magnitude of effect for the individual CVD RFs, and whether differences in RA treatment patterns by CVD status may mediate this relationship is warranted. This will help determine if CVD RFs are truly poor prognostic markers for RA outcomes.

Table. Multivariable linear regression of disease activity outcomes and functional status at baseline according to CVD status.

β – coefficient (95% CI); p-value

DAS28-ESR

CDAI

SJC-28

HAQ-DI

No CVD / No CVD RFs

Ref

Ref

Ref

Ref

CVD

0.39 (0.03, 0.75); 0.03

2.29 (-0.85,5.43); 0.15

0.76 (-0.39, 1.92); 0.20

0.15 (-0.19, 0.31); 0.08

CVD RFs / No CVD

0.28 (0.11, 0.44), 0.001

1.70 (0.25, 3.14); 0.02

0.39 (-0.14, 0.92); 0.15

0.20 (0.12, 0.27);<0.0001

Models adjusted for age and gender; furthermore, variables that were significantly associated with both CVD status and disease outcomes were also considered (e.g. education, other comorbidities, annual household income, and health insurance coverage)


Disclosure: K. Cui, None; M. Movahedi, None; C. Bombardier, Pfizer, Inc., 2; B. Kuriya, None.

To cite this abstract in AMA style:

Cui K, Movahedi M, Bombardier C, Kuriya B. Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-disease-risk-factors-may-negatively-impact-rheumatoid-arthritis-disease-outcomes-findings-from-the-ontario-best-practices-research-initiative/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-disease-risk-factors-may-negatively-impact-rheumatoid-arthritis-disease-outcomes-findings-from-the-ontario-best-practices-research-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology